Clinical updates on carvedilol: a first choice β-blocker in the treatment of cardiovascular diseases

Bibliography

• Mathers C, Lopez A, Murray CJ. Global burden of disease and risk factors. Oxford University Press, New York; 2006
   Google Scholar
• Lopez AD, Mathers CD, Ezzati M, Global and regional burden of risk factors, 2001: systematic analysis of population health data. Lancet 2006;367:1747-57
   PubMed Web of Science ®Google Scholar
• Leeder S, Raymond S, Greenberg H, A race against time: the challenge of cardiovascular disease in developing countries. Trustees of Columbia University, New York; 2004
   Google Scholar
• Steg PG, Bhatt DL, Wilson PW, One year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-206
   PubMed Web of Science ®Google Scholar
• Tardif JC. Heart rate as a treatable cardiovascular risk factor. Br Med Bull 2009;90:71-84
   PubMed Web of Science ®Google Scholar
• Fonarow GC. Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. Expert Opin Pharmacother 2006;18:2533-46
   Google Scholar
• Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000;61:3049-56
   PubMed Web of Science ®Google Scholar
• Boer RA, Veldhuisen DJ. ACE-inhibitors, beta-blockers or the combination in heart failure: is it just an A–B–C? Cardiovasc Drugs Ther 2008;22:261-3
   PubMed Web of Science ®Google Scholar
• Kaplan N. Systemic hypertension: therapy. In: Zipes D, Libby P, Bonow R, editors, Braunwald's heart disease. A textbook of cardiovascular medicine. 7th edition. Elsevier Saunders, Philadelphia, Pensylvania; 2005
   Google Scholar
• Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B editors, Drugs for the heart. 6th edition. WB Saunders Company, Philadelphia, Pensylvania; 2005
   Google Scholar
• Frishman WH. Carvedilol. N Engl J Med 1998;339:1759-65
   PubMed Web of Science ®Google Scholar
• Sica DA. Beta-blockers in hypertension: a reassessment of the benefit of combined alpha-/beta-blockade. J Clin Hypertens 2007;9:4-9
   Google Scholar
• Broeders MA, Doevendans PA, Bekkers BC, Nebivolol: a third generation beta-blocker that augments vascular nitric oxide release; endothelial beta (2)-adrenergic receptor- mediated nitric oxide production. Circulation 2000;102:677-84
   PubMed Web of Science ®Google Scholar
• Rxlist. The Internet Drug Index. Available from: http://www.rxlist.com/script/main/hp.asp. [Last accessed 7 September 2009]
   Google Scholar
• Ruffolo RR, Gellai M, Hieble JR, The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38:S82-8
   PubMed Web of Science ®Google Scholar
• Luo CH, Rudy Y. A model of the ventricular cardiac action potential. Depolarization, repolarization, and their interaction. Circ Res 1991;68:1501-26
   PubMed Web of Science ®Google Scholar
• Davidenko JM, Antzelevitch C. Electrophysiological mechanisms underlying rate-dependent changes of refractoriness in normal and segmentally depressed canine Purkinje fibers. The characteristics of post-repolarization refractoriness. Circ Res 1986;58:257-68
   PubMed Web of Science ®Google Scholar
• Kanoupakis EM, Manios EG, Mavrakis HE, Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. Cardiovasc Drugs Ther 2008;22:169-76
   PubMed Web of Science ®Google Scholar
• Nessler J, Nessler B, Kitliński M, Sudden cardiac death risk factors in patients with heart failure treated with carvedilol. Kardiol Pol 2007;65:1417-22
   PubMed Web of Science ®Google Scholar
• Hamaad A, Lip GY, Nicholls D, MacFadyen RJ. Comparative dose titration responses to the introduction of bisoprolol or carvedilol in stable chronic systolic heart failure. Cardiovasc Drugs Ther 2007;21:437-44
   PubMed Web of Science ®Google Scholar
• Sevimli S, Yilmaz M, Gundogdu F, Carvedilol therapy is associated with an improvement in left atrial appendage function in patients with congestive heart failure. Echocardiography 2007;24:623-28
   PubMed Web of Science ®Google Scholar
• Nakamura K, Kusano K, Nakamura Y, Carvedilol decreases elevated oxidative stress in human failing myocardium. Circulation 2002;105:2867-71
   PubMed Web of Science ®Google Scholar
• Sawyer DB, Siwik DA, Xiao L, Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol 2002;34:379-88
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Shah AM. Oxidative stress in heart failure. More than just damage. Eur Heart J 2003;24:2161-63
   PubMed Web of Science ®Google Scholar
• Remondino A, Kwon SH, Communal C, Beta adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2- terminal kinase-dependent activation of the mitochondrial pathway. Circ Res 2003;92:136-8
   PubMed Web of Science ®Google Scholar
• Kawai K, Qin F, Shite J, Importance ofantioxidant and antiapoptotic effects of beta-receptor blockers in heart failure therapy. Am J Physiol Heart Circ Physiol 2004;287:H1003-12
   PubMed Web of Science ®Google Scholar
• Feuerstein GZ, Shusterman NH, Ruffolo RR Jr. Carvedilol update IV: prevention of oxidative stress, cardiac remodeling and progression of congestive heart failure. Drugs Today 1997;33:453-73
   Web of Science ®Google Scholar
• Santos DJ, Moreno AJ. Inhibition of heart mitochondrial lipid peroxidation by non-toxic concentrations of carvediolol and its analog BM-910228. Biochem Pharmacol 2001;61:155-64
   PubMed Web of Science ®Google Scholar
• Banach, M, Okonski P, Kosmider A, Aortic valve replacement in patients with heart failure. Pol Merkur Lekarski 2006;20:642-45
   PubMedGoogle Scholar
• Feuerstein GZ, Ruffolo RR. Carvedilol, a novel vasodilating beta-blocker with the potential for cardiovascular organ protection. Eur Heart J 1996;17:24-9
   PubMed Web of Science ®Google Scholar
• Kowalski J, Błaszczyk J, Petecka E, Neutrophils superoxide anion generation during carvedilol therapy in patients with stable angina. Int J Cardiol 2005;102:397-402
   PubMed Web of Science ®Google Scholar
• Tadolini B, Franconi F. Carvedilol inhibition of lipid peroxidation. A new antioxidative mechanism. Free Radic Res 1998;5:377-87
   Google Scholar
• Bajcetic M, Kokic Nikolic A, Djukic M, Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study. Clin Ther 2008;30:702-14
   PubMed Web of Science ®Google Scholar
• Kastratović DA, Vasiljević ZM, Spasić MB, Carvedilol increases copper-zinc superoxide dismutase activity in patients with acute myocardial infarction. Basic Clin Pharmacol Toxicol 2007;101:138-42
   PubMed Web of Science ®Google Scholar
• Kowalski J, Banach M, Barylski M, Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 2008;13:230-39
   PubMed Web of Science ®Google Scholar
• Gilbert EM, Abraham WT, Olsen S, Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996;94:2817-25
   PubMed Web of Science ®Google Scholar
• Di Lenarda A, Sabbadini G, Salvatore L, Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. J Am Coll Cardiol 1999;33:1926-34
   PubMed Web of Science ®Google Scholar
• Kukin ML, Kalman J, Charney RH, Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51
   PubMed Web of Science ®Google Scholar
• Metra M, Giubbini R, Nodari S, Differential effects of beta-blockers in patients with heart failure: a prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol. Circulation 2000;102:546-51
   PubMed Web of Science ®Google Scholar
• Poole-Wilson PA, Swedberg K, Cleland JG, Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomized controlled trial. Lancet 2003;362:7-13
   PubMed Web of Science ®Google Scholar
• Kataoka M, Satoh T, Yoshikawa T, Comparison of the effects of carvedilol and metoprolol on exercise ventilatory efficiency in patients with congestive heart failure. Circ J 2008;72:358-63
   PubMed Web of Science ®Google Scholar
• Haghjoo M, Saravi M, Hashemi MJ, Optimal beta-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm 2007;4:1170-4
   PubMed Web of Science ®Google Scholar
• Mrdovic IB, Savic LZ, Perunicic JP, Randomized active-controlled study comparing effects of treatment with carvedilol versus metoprolol in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 2007;154:116-22
   PubMed Web of Science ®Google Scholar
• Acikel S, Bozbas H, Gultekin B, Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol 2009; 135:393-6
   PubMed Web of Science ®Google Scholar
• Widmann L, van der Does R, Hörrmann M, Machwirth M. Safety and antihypertensive efficacy of carvedilol and atenolol alone and in combination with hydrochlorothiazide. Eur J Clin Pharmacol 1990;38:S143-6
   PubMed Web of Science ®Google Scholar
• Giugliano D, Acampora R, Marfella R, Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-9
   PubMed Web of Science ®Google Scholar
• Merritt JC, Niebauer M, Tarakji K, Comparison of effectiveness of carvedilol versus metoprolol or atenolol for atrial fibrillation appearing after coronary artery bypass grafting or cardiac valve operation. Am J Cardiol 2003;92:735-6
   PubMed Web of Science ®Google Scholar
• Tomlinson B, Cronin CJ, Graham BR, Prichard BN. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol and labetalol. J Cardiovasc Pharmacol 1987;10:S69-75
   PubMedGoogle Scholar
• Lin HC, Yang YY, Hou MC, Acute administration of carvedilol is more effective than propranolol plus isosorbide-5-mononitrate in the reduction of portal pressure in patients with viral cirrhosis. Am J Gastroenterol 2004;99:1953-8
   PubMed Web of Science ®Google Scholar
• Herman RB, Jesudason PJ, Mustafa AM, Differential effects of carvedilol and atenolol on plasma noradrenaline during exercise in humans. Br J Clin Pharmacol 2003;55:134-8
   PubMed Web of Science ®Google Scholar
• Powers DR, Wallin JD. End-stage renal disease in specific ethnic and racial groups: risk factors and benefits of antihypertensive therapy. Arch Int Med 1998;158:793-800
   PubMed Web of Science ®Google Scholar
• Ferdinand KC. Treating the African American with hypertension: does race really matter? South Med J 2000;93(5):541-4
   PubMed Web of Science ®Google Scholar
• Jawa A, Nachimuthu S, Pendergrass M, Beta-blockers have a beneficial effect upon endothelial function and microalbuminuria in African-American subjects with diabetes and hypertension. J Diabetes Complications 2008;22:303-8
   PubMed Web of Science ®Google Scholar
• Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl 1999;17(1):S19-24
   PubMedGoogle Scholar
• Doehner W, Rauchhaus M, Ponikowski P, Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-26
   PubMed Web of Science ®Google Scholar
• Shindler DM, Kostis JB, Yusuf S, Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 1996;77:1017-20
   PubMed Web of Science ®Google Scholar
• Kovacic D, Marinsek M, Gobec L, Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008;97:24-31
   PubMed Web of Science ®Google Scholar
• Phillips RA, Fonseca V, Katholi RE, Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. J Cardiometab Syndr 2008;3:211-17
   PubMedGoogle Scholar
• Javaheri S, Parker TJ, Liming JD, Sleep apnea in 81 ambulatory male patients with stable heart failure: types and their prevalences, consequences, and presentations. Circulation 1998;97:2154-9
   PubMed Web of Science ®Google Scholar
• Sin DD, Fitzgerald F, Parker JD, Risk factors for central and obstructive sleep apnea in 450 men and women with congestive heart failure. Am J Respir Crit Care Med 1999;160:1101-6
   PubMed Web of Science ®Google Scholar
• Tamura A, Kawano Y, Kadota J. Carvedilol reduces the severity of central sleep apnea in chronic heart failure. Circ J 2009;73:295-8
   PubMed Web of Science ®Google Scholar
• Agostoni P, Contini M, Magini A, Carvedilol reduces exercise-induced hyperventilation: A benefit in normoxia and a problem with hypoxia. Eur J Heart Fail 2006;8:729-35
   PubMed Web of Science ®Google Scholar
• Agostoni P, Contini M, Cattadori G, Lung function with carvedilol and bisoprolol in chronic heart failure: is beta selectivity relevant? Eur J Heart Fail 2007;9:827-33
   PubMed Web of Science ®Google Scholar
• Morgan T. Clinical pharmacokinetics and pharmacodynamics of carvedilol. Clin Pharmacokinet 1994;26:335-46
   PubMed Web of Science ®Google Scholar
• Ruffolo RR Jr, Boyle DA, Venuti RP, Lukas MA. Preclinical and clinical pharmacology of carvedilol. J Hum Hypertens 1993;7:S2-15
   PubMedGoogle Scholar
• Tenero D, Boike S, Boyle D, Steady-state pharmacokinetics of carvedilol and its enantiomers in patients with congestive heart failure. J Clin Pharmacol 2000;40:844-53
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Akpan W, von Möllendorff E, Pharmacokinetics and disposition of carvedilol in humans. J Cardiovasc Pharmacol 1987;10:S85-8
   PubMedGoogle Scholar
• Frishman WH. Carvedilol. N Engl J Med 1998;339:1759-65
   PubMed Web of Science ®Google Scholar
• Neugebauer G, Gabor M, Reiff K. Disposition of carvedilol enantiomers in patients with liver cirrhosis: evidence for disappearance of stereoselective fi rst-pass extraction. J Cardiovasc Pharmacol 1992;19:S142-6
   PubMed Web of Science ®Google Scholar
• Gehr TW, Tenero DM, Boyle DA, The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency. Eur J Clin Pharmacol 1999;55:269-77
   PubMed Web of Science ®Google Scholar
• Remme WJ, Cleland JG, Erhardt L, Effect of carvedilol and metoprolol on the mode of death in patients with heart failure. Eur J Heart Fail 2007;9:1128-35
   PubMed Web of Science ®Google Scholar
• Kountz DS. Are tolerability concerns a class effect of beta-blockers in treating patients with hypertension? Postgrad Med 2009;121:14-24
   PubMed Web of Science ®Google Scholar
• Rhodes J, Margossian R, Darras BT, Safety and efficacy of carvedilol therapy for patients with dilated cardiomyopathy secondary to muscular dystrophy. Pediatr Cardiol 2008;29:343-51
   PubMed Web of Science ®Google Scholar
• Lainscak M, Moullet C, Schön N, Tendera M. Treatment of chronic heart failure with carvedilol in daily practice: the SATELLITE survey experience. Int J Cardiol 2007;122:149-55
   PubMed Web of Science ®Google Scholar
• Laer S, Mir TS, Behn F, Carvedilol therapy in pediatric patients with congestive heart failure: a study investigating clinical and pharmacokinetic parameters. Am Heart J 2002;143:916-22
   PubMed Web of Science ®Google Scholar
• Albers S, Meibohm B, Mir TS, Läer S. Population pharmacokinetics and dose simulation of carvedilol in paediatric patients with congestive heart failure. Br J Clin Pharmacol 2008;65:511-22
   PubMed Web of Science ®Google Scholar
• Del Sindaco D, Pulignano G, Cioffi G, Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. J Cardiovasc Med 2007;8:675-82
   Google Scholar
• Weir MR. Beta-blockers in the treatment of hypertension: are there clinically relevant differences? Postgrad Med 2009;121:90-8
   PubMed Web of Science ®Google Scholar
• Che Q, Schreiber MJ Jr, Rafey MA. Beta-blockers for hypertension: Are they going out of style? Cleve Clin J Med 2009;76:533-42
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97
   PubMed Web of Science ®Google Scholar
• Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69
   PubMed Web of Science ®Google Scholar
• Williams B, Poulter NR, Brown MJ, British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328:634-40
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen SE, ; for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Sever PS, Poulter NR, ; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006;7:61-3
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, ; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Drugs.com. Drug information Online. Available from: http://www.drugs.com/sfx/carvedilol-side-effects.html. [Last assessed 6 September 2009]
   Google Scholar
• Skolnik NS, Beck JD, Clark M. Combination antihypertensive drugs: recommendations for use. Am Fam Physician 2000;61:3049-56
   PubMed Web of Science ®Google Scholar
• Brook CS, Chen W, Spoors PG. Carvedilol phosphate salts and/or solvates thereof, corresponding compositions and/or methods of treatment. US7268156; 2007
   Google Scholar
• Chakraborty S, Shukla D, Jain A, Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. J Colloid Interf Sci 2009;335:242-49
   PubMed Web of Science ®Google Scholar
• Nemergut G. Review of carvedilol in extended-release formulation. J Pharm Soc Wis 2007;9:46-9
   Google Scholar
• Henderson LS, Tenero DM, Baidoo CA, Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. Am J Cardiol 2006;98:17L-26L
   PubMed Web of Science ®Google Scholar
• Packer M, Lukas MA, Tenero DM, Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction. Am J Cardiol 2006;98:39L-45L
   PubMed Web of Science ®Google Scholar
• Lemmer B. The importance of circadian rhythms on drug response in hypertension and coronary heart disease–from mice and man. Pharmacol Ther 2006;111:629-51
   PubMed Web of Science ®Google Scholar
• Tenero DM, Henderson LS, Baidoo CA. Pharmacokinetic Properties of a New Controlled-Release Formulation of Carvedilol. Am J Cardiol 2006;98(Suppl):5L-16L
   PubMedGoogle Scholar
• Chakraborty S, Shukla D, Mishra B, Singh S. Lipid–An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009;73:1-15
   PubMed Web of Science ®Google Scholar